Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Receives $15.62 Consensus Target Price from Analysts

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has earned a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $15.6250.

A number of brokerages have weighed in on ADIL. Alliance Global Partners began coverage on shares of Adial Pharmaceuticals in a research report on Monday, August 3rd. They set a “buy” rating and a $11.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Friday, July 17th. Needham & Company LLC downgraded shares of Adial Pharmaceuticals to a “buy” rating in a research note on Monday, June 15th. Loop Capital set a $6.00 target price on shares of Adial Pharmaceuticals in a research note on Monday, June 15th. Finally, Brookline Capital Markets lowered shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th.

Insider Activity

In related news, major shareholder Coastlands Capital Lp bought 10,053 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were acquired at an average cost of $2.79 per share, for a total transaction of $28,047.87. Following the acquisition, the insider owned 383,375 shares in the company, valued at $1,069,616.25. This represents a 2.69% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders bought a total of 36,753 shares of company stock valued at $97,638 in the last ninety days. 1.86% of the stock is currently owned by company insiders.

Institutional Trading of Adial Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of Adial Pharmaceuticals during the third quarter worth $51,000. Jane Street Group LLC grew its holdings in Adial Pharmaceuticals by 887.3% during the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after purchasing an additional 109,500 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in Adial Pharmaceuticals during the 4th quarter valued at $562,000. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Price Performance

Shares of NASDAQ ADIL opened at $3.98 on Tuesday. The company has a 50-day simple moving average of $2.83 and a 200-day simple moving average of $2.59. The company has a market cap of $8.53 million, a PE ratio of -0.50 and a beta of 1.39. Adial Pharmaceuticals has a 12 month low of $1.31 and a 12 month high of $10.75.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its quarterly earnings data on Friday, May 8th. The company reported ($1.48) EPS for the quarter, beating analysts’ consensus estimates of ($2.73) by $1.25.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.